

Testimony Senate Bill No. 2293 Senate Human Services Committee Senator Judy Lee, Chairwoman

January 29, 2025

Chairwoman Lee, and members of the Senate Human Services

Committee, I am Jason Wahl, Director of the Medical Marijuana Program
with the Department of Health and Human Services (Department). I
appear before you in support of Senate Bill No. 2293.

Section 1 of the bill modifies two definitions in North Dakota Century Code Section 19-24.1.01:

- Cannabinoid concentrate: types of concentrates include vape cartridges, waxes, shatter, and other dabble forms. While maximum amounts or limits exist for the four types of medical cannabinoid products, no maximum exists for concentrates. For example, state law identifies a maximum packaging size for a cannabinoid solution is 30 milliliters. Since a concentrate is an extract and nothing can be added to a concentrate, placing a packaging limit on concentrates would be a reasonable route to pursue. Currently, concentrates are packaged in half gram and one gram amounts. The Department supports a maximum one gram packaging size for concentrates.
- Designated caregiver: prior to the 2019 Legislative Session, state law clearly identified a designated caregiver had to be 21 years of age or older. A change to language related to designated caregivers inadvertently removed the 21 years of age minimum requirement. The Department supports adding this requirement back into state law.

Section 2 proposes adding language to state law to allow the Department to accept other documentation for a qualifying patient application. There may be instances when an individual is unable to obtain a current or valid identification. For example, an individual who may be bedridden or unable to leave their residency is going to have a difficult, if not impossible, time getting to a proper location to get a renewal of their driver's license or to obtain a non-driver photo identification. The Department supports adding language to state law to provide flexibility on the documentation that may be submitted for certain qualifying patients.

This concludes my testimony. I am happy to answer questions you may have.